News

Filter

1 to 9 of 35 results

Orexo gets £5 million milestone for Abstral in Europe; Zubsolv continues strong growth in the USA

Orexo gets £5 million milestone for Abstral in Europe; Zubsolv continues strong growth in the USA

18-12-2014

The annual sales in Europe of Abstral, a rapidly-disintegrating, sublingual formulation of fentanyl,…

AbstralFinancialKyowa Hakko KirinLicensingNeurologicalOrexoPharmaceuticalProStrakanZubsolv

Pfizer and Kyowa Hakko collaborate on immuno-oncology combination study

Pfizer and Kyowa Hakko collaborate on immuno-oncology combination study

30-09-2014

US pharma major Pfizer and Japanese drugmaker Kyowa Hakko Kirin have entered into an agreement to explore…

ImmunologicalsKyowa Hakko KirinmogamulizumabOncologyPF-05082566PfizerPharmaceuticalResearchUSA

Kyowa Hakko Kirin subsidiary ProStrakan acquires Archimedes

Kyowa Hakko Kirin subsidiary ProStrakan acquires Archimedes

06-08-2014

Japanese drugmaker Kyowa Hakko Kirin subsidiary, the Scotland-based ProStrakan, has acquired Archimedes…

ArchimedesArchimedes PharmaFentanylJapanKyowa Hakko KirinMergers & AcquisitionsNovo A/SNovo NordiskPharmaceuticalProStrakan

Kyowa Hakko Kirin files for KW-3357 approval in Japan

Kyowa Hakko Kirin files for KW-3357 approval in Japan

01-08-2014

Japanese drugmaker Kyowa Hakko Kirin has filed an application for marketing approval with the Ministry…

HematologyJapanKW-3357Kyowa Hakko KirinPharmaceuticalRare diseasesRegulationThrombus

AstraZeneca and Kyowa Hakko Kirin sign immunotherapy research deal

AstraZeneca and Kyowa Hakko Kirin sign immunotherapy research deal

30-07-2014

Anglo-Swedish pharma major AstraZeneca today announced that it has entered into a clinical study collaboration…

AstraZenecaBriggs MorrisonImmunologyJapanKyowa Hakko KirinOncologyPharmaceuticalResearchUK

Kyowa Hakko to acquire Archimedes for £230 million

Kyowa Hakko to acquire Archimedes for £230 million

11-07-2014

Through its Scotland-based subsidiary ProStrakan Group, Japanese drugmaker Kyowa Hakko Kirin has entered…

ArchimedesArchimedes PharmaBusiness FinanceDriverHealth Medical PharmaKyowa Hakko KirinMergers & AcquisitionsNeurologicalNovo A/SOncologyPharmaceuticalPharmaceutical industryProStrakanUK

Additional indication in Japan for Kyowa Hakko’s Poteligeo

Additional indication in Japan for Kyowa Hakko’s Poteligeo

18-03-2014

Japanese drugmaker Kyowa Hakko Kirin has received approval for additional indication for relapsed or…

Kyowa Hakko KirinOncologyPharmaceuticalPoteligeoRegulation

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

29-01-2014

After an initial decline driven by generic and biosimilar competition in the G7 (USA, Japan, France,…

AbbVieAmgenAstellas PharmaAstraZenecaGlobalKyowa Hakko KirinMarkets & MarketingNephrology and HepatologyPharmaceuticalRegpararoxadustatSensiparvelcalcetide

1 to 9 of 35 results

COMPANY SPOTLIGHT

Menarini

Back to top